Bridgeway Capital Management’s Gain Therapeutics GANX Stock Holding History

Bridgeway Capital Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.9K	Hold	30,004	–	–	﹤0.01%	1191
2026 Q1	$58.2K	Hold	30,004	–	–	﹤0.01%	1179
2025 Q4	$96.6K	Hold	30,004	–	–	﹤0.01%	1130
2025 Q3	$53.1K	Hold	30,004	–	–	﹤0.01%	1163
2025 Q2	$54K	Hold	30,004	–	–	﹤0.01%	1131
2025 Q1	$57.3K	Hold	30,004	–	–	﹤0.01%	1113
2024 Q4	$64.8K	Buy	+30,004	New	+$60.2K	﹤0.01%	1145
2024 Q3	–	Sell	-40,000	Closed	-$51.2K	–	1283
2024 Q2	$51.2K	Buy	40,000 +10,000	+33%	+$26K	﹤0.01%	1217
2024 Q1	$113K	Sell	30,000 -16,100	-35%	-$66.7K	﹤0.01%	1196
2023 Q4	$151K	Hold	46,100	–	–	﹤0.01%	1185
2023 Q3	$149K	Hold	46,100	–	–	﹤0.01%	1149
2023 Q2	$207K	Sell	46,100 -13,900	-23%	-$67.8K	﹤0.01%	1129
2023 Q1	$289K	Hold	60,000	–	–	0.01%	1016
2022 Q4	$188K	Buy	60,000 +20,000	+50%	+$62.5K	﹤0.01%	1099
2022 Q3	$130K	Hold	40,000	–	–	﹤0.01%	1225
2022 Q2	$144K	Hold	40,000	–	–	﹤0.01%	1158
2022 Q1	$163K	Sell	40,000 -10,000	-20%	-$41.8K	﹤0.01%	1202
2021 Q4	$267K	Hold	50,000	–	–	0.01%	1121
2021 Q3	$372K	Hold	50,000	–	–	0.01%	1118
2021 Q2	$501K	Buy	+50,000	New	+$564K	0.01%	1065

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Bridgeway Capital Management's GANX Position: Q2 2026 in Review

Bridgeway Capital Management held its Gain Therapeutics (GANX) position steady in Q2 2026 at 30,004 shares worth $60.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

Bridgeway Capital Management first reported a position in GANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $501K in Q2 2021. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Bridgeway Capital Management held 30,004 shares of Gain Therapeutics worth $60.9K as of Q2 2026.
Bridgeway Capital Management left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1191 holding.
Bridgeway Capital Management first reported a position in Gain Therapeutics in Q2 2021 and has held it in 20 quarters since.
Bridgeway Capital Management's Gain Therapeutics position peaked at $501K in Q2 2021.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.